Daily Health Headlines

Monkey Study Hints at Drug-Free Suppression of HIV

👤by Amy Norton 0 comments 🕔Friday, October 14th, 2016

THURSDAY, Oct. 13, 2016 (HealthDay News) -- Scientists may have found a way to suppress an HIV-like infection in monkeys, without the need for ongoing drug therapy.

The researchers added antibody therapy to standard drug treatment given to macaque monkeys infected with simian immunodeficiency virus (SIV). After three months, the animals were taken off the drugs, but their viral levels remained low to undetectable -- for close to two years.

Experts stressed that the animal findings need to be viewed with caution, and that many questions remain.

But, they were also hopeful this could lead to a therapy that frees at least some people from their HIV drug regimens.

An initial safety study has already started at the U.S. National Institute of Allergy and Infectious Diseases (NIAID).

The drug "cocktails" used to treat HIV -- known as combined antiretroviral therapy (ART) -- have changed the face of the HIV/AIDS epidemic in countries where they are widely available.

"ART is highly effective at keeping the virus at almost undetectable levels in the blood," said the study's senior author, Aftab Ansari. He's a professor at Emory University in Atlanta.

"But," he added, "there are still some major issues. One is that when patients stop ART, the virus comes roaring back. So they have to take the drugs every day for the rest of their lives."

That means facing the risk of long-term side effects such as heart, kidney and liver disease, type 2 diabetes and bone density loss. And, Ansari said, people on ART eventually develop resistance to the drugs they are taking, and need to switch to others.

A therapy that could essentially send HIV into remission, and release people from a lifetime drug regimen, would be a major advance, Ansari said.

For this study, his team used an antibody that targets a protein on immune system T cells called alpha4-beta7 integrin. The protein helps T cells find their way to lymph tissue in the gut.

The gut is a major reservoir for HIV, and HIV infects T cells. So Ansari reasoned that if T cells could be blocked from flocking to the gut during the acute stage of HIV infection, the T cells might be protected.

The investigators found that the alpha4-beta7 antibody seemed to do more than that.

The researchers began treatment on 18 macaques that had been infected with SIV for five weeks. The animals spent three months on ART drugs; four weeks after starting ART, the animals also began receiving infusions of either the antibody or a "control" substance, every three weeks.

Drug treatment got the animals' blood levels of SIV down. When drugs were stopped, the virus rebounded in the control group.

Monkeys treated with the antibody, on the other hand, showed a much different pattern: Six of the eight remaining in the study showed some resurgence in the virus, but it was contained within four weeks. The other two showed no SIV rebound.

No one knows whether the findings will "translate" to humans, Ansari said.

But, he added, a pilot study is under way at NIAID -- taking advantage of the fact that there is already an approved drug that is a humanized analogue of alpha4-beta7.

The drug, called vedolizumab (Entyvio), is used to treat Crohn's disease and ulcerative colitis -- two diseases in which the immune system mistakenly attacks the lining of the gut.

"I think people with HIV can really find some hope in these findings," said Marcella Flores. She's the associate director of research for amfAR, the Foundation for AIDS Research.

The "good news," she noted, is that vedolizumab already exists and can be readily tested.

But there are still plenty of questions, Flores cautioned.

A major one is whether the antibody can be helpful if it's given after the acute stage of HIV infection -- a point at which few people would know they have the virus.

Ansari agreed. "If people have been infected for years, will this work?"

Flores also noted that with antibody therapy, it's possible for people to develop their own antibodies against the treatment. That happened in three monkeys in this study.

She and Ansari also pointed to an unexpected finding: It's not clear how the antibody is working.

The idea behind the experiment was that the antibody would block "trafficking" of T cells into the gut, and prevent them from being infected and "adding fuel to the fire," Ansari said.

But the researchers saw something else that was unexpected: The resident T cells in the treated animals' guts actually expanded.

It's not clear what is going on, Ansari said. But, he added, it's possible that the antibody is somehow "rebuilding" the immune system.

Ansari also stressed that if the approach eventually pans out in humans, it would not be a "cure." It would suppress HIV without drugs, but would not eliminate it, he said.

The study was published Oct. 14 in Science.

Article Credits / Source

Amy Norton / HealthDay

Amy Norton wrote this story for HealthDay. HealthDay provides up to the minute breaking health news. Click here to view this full article from HealthDay.

SOURCES: Aftab Ansari, Ph.D., professor, pathology and laboratory medicine, Emory University School of Medicine, Atlanta; Marcella Flores, Ph.D., M.P.H., associate director, research, amfAR, The Foundation for AIDS Research, New York City; Oct. 14, 2016, Science

View More Articles From Amy Norton 🌎View Article Website

Sponsored Product

Lunar Sleep for $1.95

Lunar Sleep for $1.95

People who have trouble sleeping typically have low levels of melatonin, so melatonin supplements seem like a logical fix for insomnia. There is a high demand for sleep aids, especially in the U.S. The National Health Interview Survey done in 2002, and again in 2007, found 1.6 million US adults were using complementary and alternative sleep aids for insomnia. Lunar Sleep was a top choice. Use Promo Code: Sleep2014 and only pay $1.95 S&H.

Get Lunar Sleep for $1.95

More HIV Articles

Drug Combo Shows Early Promise for Remission of HIV

Drug Combo Shows Early Promise for Remission of HIV0

THURSDAY, Nov. 10, 2016 (HealthDay News) -- Animal research with an experimental two-drug therapy could hold clues for creating long-term HIV remission in people living with the virus, a new report says. The goal: to free patients from the need ...

Antibodies May Hold Key to HIV Suppression

Antibodies May Hold Key to HIV Suppression0

WEDNESDAY, Nov. 9, 2016 (HealthDay News) -- Antibodies may keep the HIV virus in check and one day let patients stop taking antiretroviral drugs, two new preliminary trials suggest. Researchers tried to quell HIV in 23 patients with infusions ...

Experimental Medicine Might Rescue People With Drug-Resistant HIV

Experimental Medicine Might Rescue People With Drug-Resistant HIV0

FRIDAY, Oct. 28, 2016 (HealthDay News) -- Researchers report that a new medication might revolutionize the treatment of HIV patients who don't respond to existing drugs. The intravenous drug, known as ibalizumab, is given every two weeks. It's ...

Study Discounts Myth of 'Patient Zero' in U.S. AIDS Crisis

Study Discounts Myth of 'Patient Zero' in U.S. AIDS Crisis0

WEDNESDAY, Oct. 26, 2016 (HealthDay News) -- Using genetic analyses of 40-year-old blood samples, scientists have arrived at a clearer understanding of the introduction and spread in North America of the virus that causes AIDS. One myth already ...

HIV May Hide in Tissues, Even After Treatment

HIV May Hide in Tissues, Even After Treatment0

WEDNESDAY, Oct. 26, 2016 (HealthDay News) -- HIV patients who've been treated with antiretroviral drugs still have the AIDS-causing virus in their tissues, a new study suggests. Treatment with antiretrovirals eliminates detectable levels of HIV ...

View More HIV Articles

0 Comments

Write a Comment

Your email address will not be published. Required fields are marked *

Our Mailing List

Subscribe to our mailing list to get the latest health news as it breaks!

Your information will not be shared with anyone!